The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

HealthDay News — For adult patients with hereditary hemorrhagic telangiectasia (HHT), a new, allosteric, selective activin receptor-like kinase 1 inhibitor, oral engasertib, is safe and is associated ...

HealthDay News — Adjunct corticosteroids probably reduce short-term mortality in adults with severe pneumonia or acute respiratory distress syndrome (ARDS), according to a review published online ...

Pazdur reportedly questioned whether a new FDA program called the Commissioner’s National Priority Voucher, designed to speed reviews for drugs tied to national priorities, was transparent or even ...

The Food and Drug Administration (FDA) has approved updated labeling for Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

HealthDay News — Millions of people rely on continuous glucose monitors to help manage diabetes. But a new alert from the Food and Drug Administration (FDA) warns that some sensors from Abbott may ...